Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Executive Interview: Leo's Gitte Aabo Talks New Products, Business Change

This article was originally published in Scrip

Executive Summary

Denmark's dermatology-focused Leo Pharma has a new product for actinic keratosis in Phase III clinical studies and several investigational products in Phase II, potential new drugs that could continue a turnaround in business activity that just days ago included completion of the purchase of Astellas's dermatology portfolio, and over the past 12 months has seen top management reorganized and digital health and open innovation embraced.


Related Content

Executive Interview: Gitte Aabo On Leo Pharma's Innovation Strategy





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts